York Pharma Plc, a specialist dermatology company listed on London’s Alternative Investment Market (AIM), said it has purchased two wound-care products from Belgium’s Solvay Pharmaceuticals BV in a transaction that should enable York Pharma to become self-financing over a 12-month span but which involves expensive and dilutive financing arrangements.
